Carrimycin inhibits coronavirus replication by decreasing the efficiency of programmed -1 ribosomal frameshifting through directly binding to the RNA pseudoknot of viral frameshift-stimulatory element

• Main Authors: Hongying Li (Author), Jianrui Li (Author), Jiayu Li (Author), Hu Li (Author), Xuekai Wang (Author), Jing Jiang (Author), Lei Lei (Author), Han Sun (Author), Mei Tang (Author), Biao Dong (Author), Weiqing He (Author), Shuyi Si (Author), Bin Hong (Author), Yinghong Li (Author), Danqing Song (Author), Zonggen Peng (Author), Yongsheng Che (Author), Jian-Dong Jiang (Author)
• Format: Book
• Published: Elsevier, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The pandemic of SARS-CoV-2 worldwide with successive emerging variants urgently calls for small-molecule oral drugs with broad-spectrum antiviral activity. Here, we show that carrimycin, a new macrolide antibiotic in the clinic and an antiviral candidate for SARS-CoV-2 in phase III trials, decreases...